Parallel Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 8.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,030 shares of the medical instruments supplier’s stock after purchasing an additional 76 shares during the quarter. Parallel Advisors LLC’s holdings in Becton, Dickinson and were worth $207,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. bought a new stake in Becton, Dickinson and in the first quarter valued at about $105,000. Parkside Financial Bank & Trust increased its holdings in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares in the last quarter. QCI Asset Management Inc. NY increased its holdings in shares of Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares in the last quarter. Financial Architects Inc increased its holdings in shares of Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares in the last quarter. Finally, Guardian Life Insurance Co. of America increased its holdings in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after acquiring an additional 6 shares in the last quarter. Institutional investors and hedge funds own 87.12% of the company’s stock.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 over the last ninety days. 1.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company (BDX) opened at 193.06 on Friday. The firm has a market capitalization of $43.93 billion, a PE ratio of 55.91 and a beta of 1.06. The stock’s 50 day moving average price is $199.01 and its 200 day moving average price is $191.58. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the company posted $2.35 EPS. The firm’s revenue was down 5.1% compared to the same quarter last year. On average, analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/24/becton-dickinson-and-company-bdx-position-raised-by-parallel-advisors-llc.html.

BDX has been the subject of several recent analyst reports. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and lowered their price target for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. BidaskClub upgraded Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, July 17th. Finally, Bank of America Corporation restated a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $200.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.